ClinicalTrials.gg
CompletedNCT01339091Updated Jan 31, 2014Results posted

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Phase 3 interventional study of Dalbavancin and Vancomycin / Linezolid in Abscess, Wound Infection and Surgical Site Infection, sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc. Completed at 92 sites in 8 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-01-31.

Sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc (part of AbbVie) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
573
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Abscess with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Abscess · United States.

Enrollment
12th of 75
573 · median 114
Started
2011
with 5 others
Phase 3
13 of 80
none open now
Registered
38th of 80
by date
Lead sponsor
3 of 80
Durata Therapeutics Inc., an affiliate of Allergan plc

Among the 80 studies in Abscess with a site in United States, this one is the 12th largest by enrollment of the 75 interventional ones that give a count, is one of 6 that started in 2011, is one of 13 in phase 3, and was the 38th registered.

Abscess

152 studies on the registry are indexed under Abscess; 22 are open to participants now.

Browse Abscess studies →

Open to participants now

4 of the 80 studies in Abscess with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Abscess studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Abscess with a site in United States, or all of them as a file.
02

Study summary

The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a suspected or proven gram-positive bacterial skin or skin structure infection.

03

Conditions studied

  • Abscess
  • Wound Infection
  • Surgical Site Infection
  • Cellulitis
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients 18 - 85 years of age.
  2. Signed and dated document.
  3. Major abscess, surgical site infection, traumatic wound infection or cellulitis suspected or confirmed to be caused by Gram-positive bacteria.
  4. At least two (2) local signs and symptoms of ABSSSI and at least one (1) systemic sign of infection.
  5. Requires a minimum of 3 days of IV therapy.
  6. Patient willing and able to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

Patients presenting with any of the following:

  1. A to any required study drug.
  2. Pregnant or nursing females.
  3. Sustained shock.
  4. Participation in another study of an drug or device within 30 days.
  5. Receipt of a systemically or topically administered antibiotic within 14 days prior to randomization, except receipt of a single dose of a short-acting antibacterial drug 3 or more days prior to randomization.
  6. Infection due to a dalbavancin or vancomycin-resistant organism.
  7. Evidence of meningitis, necrotizing fasciitis, gas gangrene, gangrene, septic arthritis, osteomyelitis, and/or endovascular infection.
  8. Exclusively gram-negative bacterial or a fungal ABSSSI.
  9. Venous catheter infection.
  10. Infection of a diabetic foot ulcer or a decubitus ulcer.
  11. Device-related infections.
  12. Gram-negative bacteremia.
  13. Infected burns.
  14. Infected limb with critical ischemia.
  15. Superficial/simple skin and skin structure infections.
  16. Concomitant condition requiring non-study antibacterial therapy.
  17. ABSSSI requiring therapy for longer than 14 days.
  18. Adjunctive therapy with hyperbaric oxygen.
  19. More than 2 surgical interventions for ABSSSI anticipated.
  20. Chronic inflammatory condition precluding assessment of clinical response.
  21. \< 500 cells/mm3.
  22. (HIV) infection with a \< 200 cells/mm3.
  23. Recent bone marrow transplant, > 20 mg prednisolone per day (or equivalent) or receiving drugs after organ transplantation.
  24. Regular, chronic antipyretic use in patients unable to modify during the first three days of study drug therapy.
  25. less than 3 months.
  26. Conditions that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results.
  27. Prior participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
573 participants (actual)

Study arms

  • Experimental
    Dalbavancin

    Drug: Dalbavancin

  • Active comparator
    Vancomycin with possible switch to oral linezolid

    Drug: Vancomycin / Linezolid

Interventions

  • IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8

  • DrugVancomycin / Linezolid

    Drug pages: VancomycinStudies of VancomycinVancomycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LinezolidStudies of LinezolidLinezolid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.

06

What researchers measure

Primary outcomes

  1. Early Clinical Efficacy

    Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature

    Time frame: 48-72 hours after the initiation of study therapy

Secondary outcomes

  1. >= 20% Reduction in Lesion Area

    Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size

    Time frame: 48-72 hours after the initiation of study therapy

  2. Clinical Status

    Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics

    Time frame: End of Treatment Visit (Day 14-15)

  3. Clinical Status

    Compare the clinical efficacy at the day 28 follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics

    Time frame: Follow-Up Visit (day 28)

07

Results

Posted Dec 25, 2013

Participant flow

Participant flow — Overall Study
MilestoneDalbavancinVancomycin +/- Oral Linezolid
Started288285
Safety population284284
Completed261257
Not completed2728

Outcome measures

PrimaryEarly Clinical Efficacy

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size and temperature

Time frame:
48-72 hours after the initiation of study therapy
Reported as:
Number · participants
Early Clinical Efficacy
participantsDalbavancinVancomycin +/- Oral Linezolid
Clinical Responder240233
Clinical Non-Responder4852
Statistical analysis
  • Dalbavancin vs Vancomycin +/- Oral Linezolid · Difference in proportions: 1.5 · 95% CI -4.6 to 7.9Confidence intervals were adjusted for fever at baseline
Secondary>= 20% Reduction in Lesion Area

Clinical response at 48-72 hours post study drug initiation, based on measurements of acute bacterial skin and skin structure infections (ABSSSI) lesion size

Time frame:
48-72 hours after the initiation of study therapy
Reported as:
Number · participants
>= 20% Reduction in Lesion Area
participantsDalbavancinVancomycin +/- Oral Linezolid
Clinical Responder259259
Clinical Non-Responder2926
SecondaryClinical Status

Compare the clinical efficacy at end of treatment visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics

Time frame:
End of Treatment Visit (Day 14-15)
Reported as:
Number · participants
Clinical Status
participantsDalbavancinVancomycin +/- Oral Linezolid
Clinical Success214222
Clinical Failure3221
SecondaryClinical Status

Compare the clinical efficacy at the day 28 follow-up visit of dalbavancin to the comparator regimen based on lesion size, local signs, temperature and receipt of non-study antibiotics

Time frame:
Follow-Up Visit (day 28)
Reported as:
Number · participants
Clinical Status
participantsDalbavancinVancomycin +/- Oral Linezolid
Clinical Success212220
Clinical Failure149

Adverse events

Collected over Begins from the time that the patient provides informed consent through the last follow up visit, Day 70. Any SAE occurring any time after the reporting period must be promptly reported if a causal relationship to investigational product is suspected.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dalbavancin—5/284 (1.8%)36/284 (12.7%)
Vancomycin +/- Oral Linezolid—12/284 (4.2%)54/284 (19%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventDalbavancinVancomycin +/- Oral Linezolid
Arthritis bacterialInfections and infestations1/2840/284
BacteraemiaInfections and infestations1/2840/284
Embolic pneumoniaInfections and infestations1/2840/284
Abscess limbInfections and infestations0/2841/284
CellulitisInfections and infestations0/2841/284
Diabetic foot infectionInfections and infestations0/2841/284
Rectal abscessInfections and infestations0/2841/284
Atrial fibrillationCardiac disorders1/2840/284
Cardiac failureCardiac disorders0/2841/284
Cardiac failure acuteCardiac disorders0/2841/284
Most frequent other events
Most frequent other events
EventDalbavancinVancomycin +/- Oral Linezolid
HeadacheNervous system disorders14/28414/284
NauseaGastrointestinal disorders12/28413/284
DiarrhoeaGastrointestinal disorders4/28411/284
PruritusSkin and subcutaneous tissue disorders1/28411/284
HypertensionVascular disorders7/2847/284
RashSkin and subcutaneous tissue disorders6/2846/284
VomitingGastrointestinal disorders3/2846/284
AstheniaGeneral disorders1/2846/284
Dermatitis contactSkin and subcutaneous tissue disorders1/2846/284

Baseline characteristics

Age, Continuous
Age, Continuous(years)DalbavancinVancomycin +/- Oral LinezolidTotal
Mean48.8 ± 15.348.9 ± 15.0848.9 ± 15.18
Sex: Female, Male
Sex: Female, Male(Participants)DalbavancinVancomycin +/- Oral LinezolidTotal
Female118112230
Male170173343
08

Study locations

92 sites
  • Durata Study Site
    Anaheim, California 92804, United States
  • Durata Study Site
    Azusa, California 91702, United States
  • Durata Study Site
    Bellflower, California 90706, United States
  • Durata Study Site
    Buena Park, California 90620, United States
  • Durata Study Site
    Carmel, California 46032, United States
  • Durata Study Site
    Chula Vista, California 92911, United States
  • Durata Study Site
    Covina, California 91723, United States
  • Durata Study Site
    Fountain Valley, California 92708, United States
  • Durata Study Site
    La Mesa, California 91942, United States
  • Durata Study Site
    Long Beach, California 90813, United States
  • Durata Study Site
    Los Alamitos, California 90720, United States
  • Durata Study Site
    Los Angeles, California 90015, United States
  • Durata Study Site
    Oceanside, California 92056, United States
  • Durata Study Site
    Palm Desert, California 92211, United States
  • Durata Study Site
    Pasadena, California 91105, United States
  • Durata Study Site
    Sacramento, California 95817, United States
  • Durata Study Site
    San Diego, California 92120, United States
  • Durata Study Site
    Santa Ana, California 92701, United States
  • Durata Study Site
    Sylmar, California 91342, United States
  • Durata Study Site
    Torrance, California 90509, United States
  • Durata Study Site
    Upland, California 91786, United States
  • Durata Study Site
    Whittier, California 90602, United States
  • Durata Study Site
    Miami, Florida 33144, United States
  • Durata Study Site
    Miami, Florida 33155, United States
  • Durata Study Site
    Orlando, Florida 32837, United States
  • Durata Study Site
    St. Cloud, Florida 34769, United States
  • Durata Study Site
    Tampa, Florida 33613, United States
  • Durata Study Site
    Columbus, Georgia 31904, United States
  • Durata Study Site
    Savannah, Georgia 31406, United States
  • Durata Study Site
    Idaho Falls, Idaho 83404, United States
  • Durata Study Site
    Pocatello, Idaho 83202, United States
  • Durata Study Site
    Moline, Illinois 61265, United States
  • Durata Study Site
    Rock Island, Illinois 31201, United States
  • Durata Study Site
    Baton Rouge, Louisiana 70808, United States
  • Durata Study Site
    Lafayette, Louisiana 70503, United States
  • Durata Clinical Site
    New Orleans, Louisiana 70112, United States
  • Durata Study Site
    Opelousas, Louisiana 70570, United States
  • Durata Study Site
    Detroit, Michigan 48202, United States
  • Durata Study Site
    Minneapolis, Minnesota 55422, United States
  • Durata Study Site
    Las Vegas, Nevada 89109, United States
  • Durata Study Site
    Somers Point, New Jersey 08244, United States
  • Durata Study Site
    Bronx, New York 10467, United States
  • Durata Study Site
    Buffalo, New York 14215, United States
  • Durata Study Site
    Lake Success, New York 11042, United States
  • Durata Study Site
    New Hyde Park, New York 11040, United States
  • Durata Study Site
    Staten Island, New York 10305, United States
  • Durata Study Site
    Winston Salem, North Carolina 27103, United States
  • Durata Study Site
    Winston-Salem, North Carolina 27103, United States
  • Durata Study Site
    Columbus, Ohio 43215, United States
  • Durata Study Site
    Lima, Ohio 45801, United States
  • Durata Study Site
    Toledo, Ohio 43608, United States
  • Durata Study Site
    Pittsburgh, Pennsylvania 15213, United States
  • Durata Study Site
    Houston, Texas 77030, United States
  • Durata Study Site
    Houston, Texas 77036, United States
  • Durata Study Site
    Madison, Wisconsin 53717, United States
  • Durata Study Site
    Middleton, Wisconsin 53562, United States
  • Durata Study Site
    Winnipeg, Manitoba R3E 0J9, Canada
  • Durata Study Site
    Trois-Rivieres, Quebec G9A 1Y1, Canada
  • Durata Study Site
    Dubrovnik, 2000, Croatia
  • Durata Clinical Site
    Slavonski Brod, 35000, Croatia
  • Durata Study Site
    Zagreb, 10000, Croatia
  • Durata Study Site
    Zagreb, 1000, Croatia
  • Durata Clinical Site
    Tbilisi, Georgia
  • Durata Study Site
    Bochum, 44791, Germany
  • Durata Study Site
    Munster, 48149, Germany
  • Durata Study Site
    Krakow, 31-501, Poland
  • Durata Study Site
    Legionowo, 05-120, Poland
  • Durata Study Site
    Warszawa, 03-401, Poland
  • Durata Study Site
    Wroclaw, 51-124, Poland
  • Durata Study Site
    Kharkiv, Ukraine 61037, Russian Federation
  • Durata Study Site
    Kyiv city, Ukraine 02125, Russian Federation
  • Durata Study Site
    Ekaterinburg, 620095, Russian Federation
  • Durata Study Site
    Moscow, 111020, Russian Federation
  • Durata Clinical Site
    Moscow, 111539, Russian Federation
  • Durata Study Site
    Moscow, 129327, Russian Federation
  • Durata Study Site
    Perm, 614036, Russian Federation
  • Durata Study Site
    Saratov, 410053, Russian Federation
  • Durata Study Site
    Smolensk, 214018, Russian Federation
  • Durata Study Site
    St. Petersburg, 191104, Russian Federation
  • Durata Study Site
    St. Petersburg, 192242, Russian Federation
  • Durata Study Site
    St. Petersburg, 194354, Russian Federation
  • Durata Study Site
    St. Petersburg, 198099, Russian Federation
  • Durata Clinical Site
    St. Petersburg, 94354, Russian Federation
  • Durata Study Site
    Tomsk, 634064, Russian Federation
  • Durata Study Site
    Cherkasy, 18009, Ukraine
  • Durata Study Site
    Ivano-Frankivsk, 76018, Ukraine
  • Durata Study Site
    Kharkiv, 61037, Ukraine
  • Durata Study Site
    Kyiv, 02125, Ukraine
  • Durata Study Site
    Kyiv, 03110, Ukraine
  • Durata Study Site
    Uzhgorod, 88018, Ukraine
  • Durata Study Site
    Zaporizhzhya, 69032, Ukraine
  • Durata Study Site
    Zhytomyr, 10002, Ukraine
09

References and documents

Publications

  • Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials. Infect Dis Ther. 2022 Feb;11(1):423-434. doi: 10.1007/s40121-021-00568-7. Epub 2021 Dec 14. PubMed 34905144 ↗
  • Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480. PubMed 24897082 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Sep 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2011
First posted
Apr 20, 2011
Start
Mar 2011
Primary completionActual
Sep 2012
CompletionActual
Nov 2012
Results first posted
Dec 25, 2013
Last update
Jan 31, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01339091
Responsible party
Sponsor
First posted
Apr 20, 2011
Start date
Mar 2011
Primary completion
Sep 2012
Completion
Nov 2012
Results posted
Dec 25, 2013
Last update
Jan 31, 2014

Study contacts

Michael Dunne, MD
study director · Durata Therapeutics Inc., an affiliate of Allergan plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalbavancin

Start the discussion